CTLA4 and neoplasm: Indeed, in studies involving microneedle delivery of anti-CTLA-4 in an orthotopic mouse model of head and neck cancer, Gutkind and coworkers (Gilardi et al., 2022) showed anti-tumor responses at doses significantly lower than that needed using systemic administration.